Sigyn Therapeutics (SIGY) Cost of Revenue (2017 - 2025)

Sigyn Therapeutics has reported Cost of Revenue for 9 years, with the latest figure at $52.0 in Q3 2025.

• Quarterly Cost of Revenue fell 54.39% year-over-year to $52.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $906.0 (up 75.24% YoY) and the FY2024 annual result came in at $1130.0, up 188.27% from the prior year.
• Cost of Revenue grew to $52.0 in Q3 2025 per SIGY's latest filing, from $8.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $82250.0 in Q1 2021 and troughed at $8.0 in Q2 2024.
• A 5-year average of $9806.8 and a median of $114.0 in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2021 and 2022: Cost of Revenue jumped 78233.33% in 2021, then sank 99.84% in 2022.
• Over 5 years, Cost of Revenue stood at $82250.0 in 2021, then tumbled by 99.99% to $11.0 in 2022, then surged by 418.18% to $57.0 in 2023, then surged by 1075.44% to $670.0 in 2024, then slumped by 92.24% to $52.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $52.0, $8.0, and $176.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.